Postoperative progression of pulmonary metastasis in osteosarcoma.
Early relapse with distant metastasis often is observed in patients with cancer after resection of the primary tumor. It is considered that resection of the primary tumor induces activation of systemic angiogenesis and enhances progression of remote metastasis. The authors show that resection of the primary osteosarcoma tumor enhances progression of pulmonary metastasis in animal osteosarcoma models. Matrigel plug neovascularization assay revealed that systemic angiogenic activity was elevated after primary tumor removal (tumor intact group, 1.61 +/- 0.21 g/dL; tumor removed group, 4.92 +/- 0.35 g/dL). In addition, serum concentration of the angiogenesis inhibitor, endostatin, decreased significantly after primary tumor removal. Treatment with the antiangiogenic reagent TNP-470 suppressed postoperative progression of pulmonary metastasis. These results indicate the possibility that activation of angiogenic activity after resection of osteosarcoma tumors enhances progression of pulmonary metastasis. The current data also suggest that administration of antiangiogenic reagents can prevent progression of pulmonary metastasis in osteosarcoma postoperatively.
Tsunemi
Takeo
T
Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Japan.
Nagoya
Satoshi
S
Kaya
Mitsunori
M
Kawaguchi
Satoshi
S
Wada
Takuro
T
Yamashita
Toshihiko
T
Ishii
Seiichi
S
D020533:Angiogenesis Inhibitors / Q000097:blood / Q000627:therapeutic use*; D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology* / Q000517:prevention & control / Q000601:surgery*; D003094:Collagen / Q000097:blood; D003510:Cyclohexanes; D004195:Disease Models, Animal; D043169:Endostatins; D016228:Endothelial Growth Factors / Q000097:blood; D005260:Female; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000517:prevention & control* / Q000556:secondary*; D008222:Lymphokines / Q000097:blood; D051379:Mice; D008807:Mice, Inbred BALB C; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012516:Osteosarcoma / Q000517:prevention & control / Q000556:secondary* / Q000601:surgery*; D010446:Peptide Fragments / Q000097:blood; D011183:Postoperative Complications; D012717:Sesquiterpenes / Q000097:blood / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D043169:Endostatins; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D010446:Peptide Fragments; D012717:Sesquiterpenes; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D003094:Collagen; D000077609:O-(Chloroacetylcarbamoyl)fumagillol